Genome-wide whole blood transcriptome profiling in a large European cohort of systemic sclerosis patients

Objectives The analysis of annotated transcripts from genome-wide expression studies may help to understand the pathogenesis of complex diseases, such as systemic sclerosis (SSc). We performed a whole blood (WB) transcriptome analysis on RNA collected in the context of the European PRECISESADS project, aiming at characterising the pathways that differentiate SSc from controls and that are reproducible in geographically diverse populations. Methods Samples from 162 patients and 252 controls were collected in RNA stabilisers. Cases and controls were divided into a discovery (n=79+163; Southern Europe) and validation cohort (n=83+89; Central-Western Europe). RNA sequencing was performed by an Illumina assay. Functional annotations of Reactome pathways were performed with the Functional Analysis of Individual Microarray Expression (FAIME) algorithm. In parallel, immunophenotyping of 28 circulating cell populations was performed. We tested the presence of differentially expressed genes/pathways and the correlation between absolute cell counts and RNA transcripts/FAIME scores in regression models. Results significant in both populations were considered as replicated. Results Overall, 15 224 genes and 1277 functional pathways were available; of these, 99 and 225 were significant in both sets. Among replicated pathways, we found a deregulation in type-I interferon, Toll-like receptor cascade, tumour suppressor p53 protein function, platelet degranulation and activation. RNA transcripts or FAIME scores were jointly correlated with cell subtypes with strong geographical differences; neutrophils were the major determinant of gene expression in SSc-WB samples. Conclusions We discovered a set of differentially expressed genes/pathways validated in two independent sets of patients with SSc, highlighting a number of deregulated processes that have relevance for the pathogenesis of autoimmunity and SSc.

[1]  S. Assassi,et al.  Type I interferon dysregulation in Systemic Sclerosis. , 2020, Cytokine.

[2]  Javier Martín,et al.  Towards a Better Classification and Novel Therapies Based on the Genetics of Systemic Sclerosis , 2019, Current Rheumatology Reports.

[3]  B. Korman Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis. , 2019, Translational research : the journal of laboratory and clinical medicine.

[4]  M. Manetti,et al.  A new avenue in the pathogenesis of systemic sclerosis: the molecular interface between the endothelial and the nervous systems. , 2019, Clinical and experimental rheumatology.

[5]  J. Varga,et al.  Emerging targets of disease-modifying therapy for systemic sclerosis , 2019, Nature Reviews Rheumatology.

[6]  M. Bulyk,et al.  The multiple mechanisms that regulate p53 activity and cell fate , 2019, Nature Reviews Molecular Cell Biology.

[7]  T. Radstake,et al.  The Long Non-coding RNA NRIR Drives IFN-Response in Monocytes: Implication for Systemic Sclerosis , 2019, Front. Immunol..

[8]  A. Segura‐Carretero,et al.  Urinary and plasma metabolite differences detected by HPLC‐ESI‐QTOF‐MS in systemic sclerosis patients , 2019, Journal of pharmaceutical and biomedical analysis.

[9]  Nir Hacohen,et al.  Multiplexed enrichment and genomic profiling of peripheral blood cells reveal subset-specific immune signatures , 2019, Science Advances.

[10]  S. Bhattacharyya,et al.  Targeting TLRs and the inflammasome in systemic sclerosis , 2018, Pharmacology & therapeutics.

[11]  Sun Kim,et al.  Comprehensive and critical evaluation of individualized pathway activity measurement tools on pan-cancer data , 2018, Briefings Bioinform..

[12]  S. Shetty,et al.  p53 Expression in Lung Fibroblasts Is Linked to Mitigation of Fibrotic Lung Remodeling. , 2018, The American journal of pathology.

[13]  I. Parra-Rojas,et al.  AB0389 Hipertriglyceridemic-waist phenotype: a marker of cardiovascular risk in rheumatoid arthritis patients , 2018, Rheumatoid arthritis – comorbidity and clinical aspects.

[14]  Z. Modrušan,et al.  Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis , 2018, Annals of the rheumatic diseases.

[15]  Enrico Petretto,et al.  Changes in macrophage transcriptome associate with systemic sclerosis and mediate GSDMA contribution to disease risk , 2018, Annals of the rheumatic diseases.

[16]  Jae Cheol Lee,et al.  Genomic profiles of lung cancer associated with idiopathic pulmonary fibrosis , 2018, The Journal of pathology.

[17]  Fengzhi Li,et al.  Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer? , 2017, American journal of cancer research.

[18]  J. D. de Vries-Bouwstra,et al.  Antisense Long Non-Coding RNAs Are Deregulated in Skin Tissue of Patients with Systemic Sclerosis. , 2017, The Journal of investigative dermatology.

[19]  Lihua Zhang,et al.  Systematic approach to understanding the pathogenesis of systemic sclerosis , 2017, Clinical genetics.

[20]  A. Sawalha,et al.  Unfolding the pathogenesis of scleroderma through genomics and epigenomics. , 2017, Journal of autoimmunity.

[21]  M. Manetti,et al.  The “myth” of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event? , 2017, Arthritis Research & Therapy.

[22]  D. Stolz,et al.  Skin-Resident Effector Memory CD8+CD28- T Cells Exhibit a Profibrotic Phenotype in Patients with Systemic Sclerosis. , 2017, The Journal of investigative dermatology.

[23]  C. Greenwood,et al.  Novel insights into systemic autoimmune rheumatic diseases using shared molecular signatures and an integrative analysis , 2017, Epigenetics.

[24]  M. Fujimoto,et al.  Blockade of p38 Mitogen-Activated Protein Kinase Inhibits Murine Sclerodermatous Chronic Graft-versus-Host Disease. , 2017, The American journal of pathology.

[25]  Robert W. Hoffman,et al.  Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab , 2016, Arthritis & rheumatology.

[26]  J. Li Effect size measures in a two-independent-samples case with nonnormal and nonhomogeneous data , 2016, Behavior research methods.

[27]  Christophe Jamin,et al.  Multi-center harmonization of flow cytometers in the context of the European "PRECISESADS" project. , 2016, Autoimmunity reviews.

[28]  Marta E. Alarcón-Riquelme,et al.  Gene Expression and Pharmacodynamic-Induced Changes in 1 , 760 SLE Patients from Two Phase III Trials of B Cell Activating Factor Blockade with Tabalumab , 2016 .

[29]  G. Krenning,et al.  FGF2 inhibits endothelial–mesenchymal transition through microRNA-20a-mediated repression of canonical TGF-β signaling , 2016, Journal of Cell Science.

[30]  Daniel J. Gaffney,et al.  A survey of best practices for RNA-seq data analysis , 2016, Genome Biology.

[31]  Peter A. Flach,et al.  Precision-Recall-Gain Curves: PR Analysis Done Right , 2015, NIPS.

[32]  S. Ogawa,et al.  Defects in Regulatory T Cells Due to CD28 Deficiency Induce a Qualitative Change of Allogeneic Immune Response in Chronic Graft-versus-Host Disease , 2015, The Journal of Immunology.

[33]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[34]  Peipei Ping,et al.  Comparison of Whole Blood and Peripheral Blood Mononuclear Cell Gene Expression for Evaluation of the Perioperative Inflammatory Response in Patients with Advanced Heart Failure , 2014, PloS one.

[35]  Hanspeter Pfister,et al.  UpSet: Visualization of Intersecting Sets , 2014, IEEE Transactions on Visualization and Computer Graphics.

[36]  M. Jinnin,et al.  Serum levels of matrix metalloproteinase‐13 in patients with eosinophilic fasciitis , 2014, The Journal of dermatology.

[37]  E. Donadi,et al.  Patients with Systemic Sclerosis Present Increased DNA Damage Differentially Associated with DNA Repair Gene Polymorphisms , 2014, The Journal of Rheumatology.

[38]  Charity W. Law,et al.  voom: precision weights unlock linear model analysis tools for RNA-seq read counts , 2014, Genome Biology.

[39]  M. Mayes,et al.  What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis? , 2013, Current opinion in rheumatology.

[40]  Oliver Distler,et al.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. , 2013, Arthritis and rheumatism.

[41]  M. Mayes,et al.  An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative , 2013 .

[42]  S. Shen-Orr,et al.  Computational deconvolution: extracting cell type-specific information from heterogeneous samples. , 2013, Current opinion in immunology.

[43]  Y. Lussier,et al.  Curation-free biomodules mechanisms in prostate cancer predict recurrent disease , 2013, BMC Medical Genomics.

[44]  Yong Huang,et al.  Single Sample Expression-Anchored Mechanisms Predict Survival in Head and Neck Cancer , 2012, PLoS Comput. Biol..

[45]  R. Silver,et al.  Coagulation and autoimmunity in scleroderma interstitial lung disease. , 2011, Seminars in arthritis and rheumatism.

[46]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[47]  Marcel Martin Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[48]  Inke R. König,et al.  Validation in Genetic Association Studies , 2011, Briefings Bioinform..

[49]  Kenneth G. C. Smith,et al.  Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in systemic lupus erythematosus and vasculitis , 2009, Annals of the rheumatic diseases.

[50]  A. Postlethwaite,et al.  Platelet contributions to the pathogenesis of systemic sclerosis , 2007, Current opinion in rheumatology.

[51]  S. Akira,et al.  Toll-like Receptors and Type I Interferons* , 2007, Journal of Biological Chemistry.

[52]  Sung-Hwan Park,et al.  Elevated matrix metalloproteinase-9 in patients with systemic sclerosis , 2004, Arthritis research & therapy.

[53]  D. Shegogue,et al.  Role of p38 MAPK in transforming growth factor beta stimulation of collagen production by scleroderma and healthy dermal fibroblasts. , 2002, The Journal of investigative dermatology.

[54]  L. Rudnicka,et al.  The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis , 2001, Arthritis research.

[55]  Daniel B. Rifkin,et al.  Fibroblast Growth Factor-2 (FGF-2) Induces Vascular Endothelial Growth Factor (VEGF) Expression in the Endothelial Cells of Forming Capillaries: An Autocrine Mechanism Contributing to Angiogenesis , 1998, The Journal of cell biology.

[56]  A. Nanji,et al.  Dietary linoleic acid is required for development of experimentally induced alcoholic liver injury. , 1988, Life sciences.

[57]  Xiaodong Zhou,et al.  Sirtuin1 Protects against Systemic Sclerosis‐related Pulmonary Fibrosis by Decreasing Proinflammatory and Profibrotic Processes , 2018, American journal of respiratory cell and molecular biology.

[58]  Qiang Sun,et al.  Individual-level analysis of differential expression of genes and pathways for personalized medicine , 2015, Bioinform..

[59]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[60]  M. Gerstein,et al.  RNA-Seq: a revolutionary tool for transcriptomics , 2009, Nature Reviews Genetics.

[61]  Ralph L. Rosnow,et al.  Essentials of Behavioral Research: Methods and Data Analysis , 1984 .